Current therapeutic uses of lenalidomide in multiple myeloma. - Wikidata - awgldk - TriplyDB

Current therapeutic uses of lenalidomide in multiple myeloma.

Current therapeutic uses of lenalidomide in multiple myeloma.

http://www.wikidata.org/entity/Q36376450

about

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function Immunomodulatory agents in myelofibrosis.Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells.High-throughput approaches to discover novel immunomodulatory agents for cancer.A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine.

P2860

Q28383385-F5E8E276-D971-4534-A231-DD6352C7AD92 Q33401615-1DBBF402-25FE-4BE5-A8F2-A8B8AF28A7D2 Q36394469-663EC1FB-D87B-48F0-A259-BEE117C7398B Q36744385-4C8CEC16-2FD2-4BAC-8650-A457AF1E825B Q39305248-780A8DBB-04A4-4DF6-9BC1-3F5DDBAA9BCC Q39417367-4AF59EE5-07EC-404E-A935-A30A04FF6EBC Q41435784-C2511086-430C-4635-A0D8-46B651D0996C Q42114228-C4BF6A35-9130-42EB-B65E-11CECA0F27A5 Q42403258-C528F6EA-8F79-484F-A6CE-84C804055821 Q42534665-3EC6D76A-F24E-4768-85C3-164B2E7C3075

P2860

Current therapeutic uses of lenalidomide in multiple myeloma.

http://www.wikidata.org/entity/Q36376450

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Current therapeutic uses of lenalidomide in multiple myeloma.

@ast

Current therapeutic uses of lenalidomide in multiple myeloma.

@en

type

label

Current therapeutic uses of lenalidomide in multiple myeloma.

@ast

Current therapeutic uses of lenalidomide in multiple myeloma.

@en

prefLabel

Current therapeutic uses of lenalidomide in multiple myeloma.

@ast

Current therapeutic uses of lenalidomide in multiple myeloma.

@en

P1433

Q36376450-7EF6C84A-3D72-441B-BAC3-CE37459A70D6

P1476

Q36376450-01551EEA-DE27-4386-93FC-E7C6CCDA924A

P2093

Q36376450-878E185B-EAE3-4EEB-8294-675FADC6BBAB

P2860

Q36376450-0CF90959-54FC-42D2-803A-48CF37C054C4

Q36376450-1AE36F74-3671-4CF2-B4D9-E793438E3DA4

Q36376450-1B2D5FAB-4B42-4BF9-A535-1269D116C997

Q36376450-1C451427-C013-4EA4-BEB9-D388E7B394AE

Q36376450-2262CF2F-EB13-45CB-8E48-89DFA0294B48

Q36376450-24E663B5-C3DA-4ABF-B133-698CDA8D2835

Q36376450-281F41BB-BA6E-4F57-AAD3-C478B6564DE1

Q36376450-2B3E827D-6EF1-4EEE-8BED-92A1256AF262

Q36376450-2D88733D-E756-46F1-BFD0-2A54090491BF

Q36376450-2F66D056-F7B1-48CC-9B99-FD90834A9E25

P304

Q36376450-8A43D36C-C8D5-44FA-93A0-552E4610BA32

P31

Q36376450-35C54F1D-F912-4D43-8F1F-213AD9BB34EE

P356

Q36376450-E5B6441F-B5D5-425C-9944-8F381E860B51

P407

Q36376450-7511B1BE-C279-47A4-A14D-B3B8F889F23F

P433

Q36376450-92E4DE67-FEDC-47D5-8525-9028816AA2B5

P478

Q36376450-F275C00E-C215-4EE9-9704-8C2B42171FBB

P50

Q36376450-5F87E161-AEDC-461E-BAC6-2D04B5C804BA

Q36376450-E7EA498A-D440-488B-B4E2-A357529DA0C9

P577

Q36376450-E739FE25-C8A7-47AB-9798-D2C818357667

P5875

Q36376450-DBFD5F50-7F47-4E65-9E0C-04B5DB19AD5B

P698

Q36376450-24297249-31E9-45F1-81CB-0A1277A996A6

P356

13543784.15.2.171

P1433

Expert Opinion on Investigational Drugs

P1476

Current therapeutic uses of lenalidomide in multiple myeloma.

@en

P2093

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

Antitumor activity of thalidomide in refractory multiple myeloma.

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

NF-kappa B as a therapeutic target in multiple myeloma.

Multiple myeloma: evolving genetic events and host interactions.

Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

P304

171-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.15.2.171

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7339160

http://www.w3.org/2001/XMLSchema#string

P698

16433596

http://www.w3.org/2001/XMLSchema#string